Blog

Posts

16 Nov 20

Batch Testing and Release: Life after Brexit

We at KYMOS and ASPHALION are long-time partners in providing analytical and regulatory services to international pharma and biotech sectors. Our testimony goes beyond the conventional “CRO trading with UK clients” to overcome internalization barriers. Our respective services are part of a complex international supply chain that makes the effects of Brexit more visible and quantifiable. Quality Control (QC) is one of the most interdisciplinary departments at KYMOS with high demand from international clients, particularly for EU Batch Testing and Release for drug products and IMPs.

16 Sep 20

Biopharmaceutical Global Partners

Meet Pablo Cobo: KYMOS’ key opinion leader in biologics drug development

Our head of Biopharmaceutical Testing Pablo Cobo, Chemistry graduate and biologics pioneer, remembers his early days at Ipsen when peptide product development was quite different: 

01 Jul 20

Dr Carles Celma, Scientific Director at KYMOS presents successful Biologics Seminar

Dr Carles Celma, Scientific Director at KYMOS was invited by ALMIRALL to present a one-off Biologics seminar on July 1st. The initiative, held remotely via Teams due to the COVID-19 pandemic, was promoted by  Technical R&D, Almirall R&D, and aimed to explore analytical capabilities for the characterization and quality control of biopharmaceutical products, a subject of growing importance within the healthcare community. 

10 Jun 20

ANIMAL CLINICAL R&D IN TIMES OF COVID-19

The COVID-19 pandemic has paralyzed many aspects of our lives. However, the R&D of new pharmaceutical products for animal health cannot stop as many human diseases posing a threat have an animal origin. KYMOS and its partners have a unique insight into how the industry is adapting to speed up animal studies during these uncertain times.

18 May 20

Immunology: Working together to prepare for the next pandemic

Now more than ever, immunology is a hot topic as we face the numerous challenges of the COVID19 pandemic. The world is patiently awaiting new therapies and vaccines to combat this disease in hopes of returning some sense of normalcy to our lives. 

KYMOS’ immunology expert, Dr. Carles Morte, shares his outlook on the future of promising new gene- and cell-based therapies and monoclonal antibodies developed against viral and other diseases. We talk to him about the technical evaluation required as the therapeutic target turns to the ever-so-complex immune system.